TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05437796

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hypnotic virtual reality support using hypnosis software Hypno-VR®
Description: Hypnosis software Hypno-VR® (Strasbourg, France) paired with VR headsets Oculus VR® (Menlo Park, CA, USA)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: No Hypnotic virtual reality
Description: Group without Hypnotic virtual reality
Study: NCT00586690

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NK Cell infusion using CD56 monoclonal antibody
Description: The cells from leukapheresis will be natural killer (NK) cell selected using a CD56 antibody and a cell column system provided by Miltenyi Biotec. The target cell dose for each NK cell infusion will be up to 1 X 10(7) CD56+ cells/kg patient weight with less than 0.5 X 10(6) CD3+ cells/kg patient weight. The first NK cell infusion will be administered 6 weeks post transplant in patients who have ≤ grade II acute graft versus host disease (aGVHD) at the time of infusion. Patients will be evaluated for toxicity and response until 20 weeks after the last NK Infusion.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Donor Apheresis
Description: Apheresis repeated daily up to 3 days until target dose of cells reached (preferably without donor receiving growth factors). Cells were transfused immediately after collection and processing. If collections occurred during initial mobilization at the time of stem cell transplant, the donor was off growth factor for \>24 hours. These extra cell collections from the donor were sufficient for the natural killer cells used in the trial. The cells were NK selected using a CD56 antibody (CliniMACS CD56 Reagent), CliniMACSplus instrument and CliniMACS tubing set provided by Miltenyi Biotec using the company protocol (Miltenyi Biotec Inc, Auburn, California). Pre and post processing cell count, viability, Hematopoietic Progenitor Cell Assay (HPCA) and flow analysis were done.
Study: NCT01574781

Intervention type: PROCEDURE
Intervention: Blood draw
Description: Blood is drawn at the appropriate time given their cohort inclusion.

Intervention type: PROCEDURE
Intervention: Blood draw
Description: Blood is drawn at the appropriate time given their cohort inclusion.

Intervention type: PROCEDURE
Intervention: Blood draw
Description: Blood is drawn at the appropriate time given their cohort inclusion.
Study: NCT02183428

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glyburide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356 + Glyburide
Study: NCT01574781

Intervention type: PROCEDURE
Intervention: Blood draw
Description: Blood is drawn at the appropriate time given their cohort inclusion.

Intervention type: PROCEDURE
Intervention: Blood draw
Description: Blood is drawn at the appropriate time given their cohort inclusion.

Intervention type: PROCEDURE
Intervention: Cheek swab/Saliva Sampling
Description: In lieu of blood draw, male relatives may donate cheek swab or saliva sample. Children born to participating women can donate cheek swab or saliva sample soon after birth.
Study: NCT03646292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: The investigators will compare the degree of liver fat before and after empagliflozin monotherapy.
Study: NCT02183428

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 1356 + Glyburide
Study: NCT01574781

Intervention type: PROCEDURE
Intervention: Cheek swab/Saliva Sampling
Description: In lieu of blood draw, male relatives may donate cheek swab or saliva sample. Children born to participating women can donate cheek swab or saliva sample soon after birth.
Study: NCT01199341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1981
Description: 100 mg per oral, twice daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: 10 x 2.5 mg per oral, once daily at day 1 and day 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: 10 x 2.5 mg per oral, once daily at day 1 and day 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1981
Description: 4 x 100 mg per oral, twice daily for 14 days
Study: NCT06655077

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RA PRO Dashboard
Description: The RA PRO Dashboard was developed by UCSF rheumatology investigators in collaboration with the UCSF SOMTech Unit. Briefly, investigators used a human-centered design approach to build a new, EHR-integrated, patient-facing visualization tool that displays RA outcome data to RA patients during clinical visits. The RA PRO dashboard was tailored for deployment at the UCSF Health's rheumatology clinic using a EHR side-car application (Salesforce). The dashboard was launched into the production environment in August 2021. With the launch, investigators integrated quality improvement, user monitoring, and lean management techniques to promote use of RA outcomes and the dashboard (for clinicians granted access) during clinical visits.
Study: NCT03476239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Blinatumomab will be supplied as single-use glass injection vials as a sterile, preservative-free, white to off-white, lyophilized powder for reconstitution and administration by continuous intravenous infusion (CIVI).~A single cycle of blinatumomab treatment is 6 weeks in duration, which includes 4 weeks of blinatumomab CIVI followed by a 2 week treatment-free interval. The treatment-free interval may be prolonged by up to 7 days, if deemed necessary by the investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamthasone
Description: Premedication with dexamethasone was intended to prevent cytokine release syndrome (CRS) events associated with blinatumomab treatment. Treatment could start pre-study. Dexamethasone 20 mg IV was administered within 3 hours before start of blinatumomab in each treatment cycle, and within 3 hours before dose step increase.
Study: NCT04494165

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: massage with frankincense and myyrh essential oil
Description: In addition to the standard physical therapy session, 30 patients in aromatherapy group received a total of six sessions of lumbar massage for three weeks with frankincense and myrrh essential oils, two sessions per week (2nd and 5th days of each week), each lasting 15 minutes. During the massage, an average of 3ml mixture prepared by adding 2% frankincense oil and 2% myrrh essential oil to jojoba carrier oil was used as an oil mixture.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: massage with carrier oil
Description: In addition to the standard physical therapy session, 31 patients in placebo group received a total of six sessions of lumbar massage for three weeks with jojoba oil, two sessions per week (2nd and 5th days of each week), each lasting 15 minutes.
Study: NCT00618956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milnacipran hydrochloride
Description: Milnacipran 100 to 200 mg/day tablet (administered in divided doses, twice daily \[BID\]), oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04358250

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Direct Superior Approach
Description: GROUP II :Patients positioned in lateral decubitus.landmark for incision is the apex of the greater trochanter,and skin, subcutaneous tissue except fascia are incised accordingly. Fibers of gluteus will be separated and not incised.posterior capsulotomy is performed,;femur is dislocated and neck osteotomy carried out, followed by preparation of femoral canal with progressive broach. Acetabulum is prepared with burs of increasing diameter, and acetabular cup is impacted. A polyethylene insert and a femoral rasp are subsequently introduced.All remaining definitive implants can be positioned.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: posterolateral approach
Description: GROUP I:patients are positioned in lateral decubitus.Landmark for incision is the apex of the greater trochanter.posterior capsulotomy is performed, femur is dislocated and neck osteotomy carried out, followed by preparation of femoral canal with progressive broach.Acetabulum is prepared with burs of increasing diameter,and acetabular cup is then impacted.All definitive implants can be positioned.
Study: NCT01765712

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Anterior Cruciate ligament reconstruction bone patellar tendon bone autograft
Study: NCT03263143

Intervention type: OTHER
Group type: OTHER
Intervention: Palliative Care
Description: Palliative Care Consultation within 24 to 48 hours after admission
Study: NCT01765712

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anterior Cruciate ligament reconstruction bone patellar tendon bone autograft

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Study: NCT02049567

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FluidVision AIOL
Description: Investigational implantable medical device intended for long-term use over the lifetime of the cataract subject

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract Surgery
Description: Performed using standard microsurgical techniques
Study: NCT02167269

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Baby EAR
Description: A modification of the Enclosed Afferent Reservoir anesthesia circuit (EAR) for pediatric use by adding a KKU one-way valve in the expiratory limb

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Baby EAR
Description: A modification of the Enclosed Afferent Reservoir anesthesia circuit (EAR) for pediatric use by adding a KKU one-way valve in the expiratory limb
Study: NCT04371510

Intervention type: OTHER
Group type: OTHER
Intervention: blood sample
Description: a blood sample is taken on Covid-19 chronic haemodialysis patients with moderate symptoms
Study: NCT04387474

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brain-computer interface
Description: brain-computer interface rehabilitation training.
Study: NCT01950351

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Radiation Therapy
Description: Undergo proton beam radiation therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT02171650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992
Study: NCT02622022

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00818909

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systane
Description: Systane prescription
Study: NCT03646292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of pioglitazone and empagliflozin
Description: The investigators will compare the degree of liver fat before and after pioglitazone and empagliflozin combination therapy.
Study: NCT04075864

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Counseling and Exercise
Description: exercise program combined with behavioral counseling for patients who are hospitalized with a cystic fibrosis exacerbation
Study: NCT04216004

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Controlled-Feeding Intervention
Description: All energy-containing food and beverages will be provided for 1-week as a controlled-feeding study.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Controlled-Feeding Intervention
Description: All energy-containing food and beverages will be provided for 1-week as a controlled-feeding study.
Study: NCT02905019

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: R21 with Matrix-M1
Description: Vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: R21 with Matrix-M1
Description: Vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: R21 with Matrix-M1
Description: Vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: R21 with Matrix-M1
Description: Vaccine
Study: NCT04216004

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Controlled-Feeding Intervention
Description: All energy-containing food and beverages will be provided for 1-week as a controlled-feeding study.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Non-dairy beverage
Description: Isolated amino acid, fatty acid, and monosaccharide beverage matched to the macronutrient content of 8 fl oz whole milk.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Full-fat milk
Description: 3 daily servings (cup-eq) of full-fat (3.25%) commercial cow's milk.
Study: NCT02905019

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: R21 with Matrix-M1
Description: Vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ChAd63 ME-TRAP
Description: Vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MVA ME-TRAP
Description: Vaccine
Study: NCT04216004

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fat-free milk
Description: 3 daily servings (cup-eq) of fat-free (0%) commercial cow's milk.
Study: NCT02102737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-DIG
Description: injection of 6-DIG

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: clamp
Description: hyperinsulinemic euglycemic clamp
Study: NCT03598218

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofraction radiation
Description: Hypofractionated dose IMRT: GTVnx 60Gy, GTVnd 60Gy, PTV1 50Gy and PTV2 45Gy in 25 fractions, 5 days/week.~Induced chemotherapy: Paclitaxel 135mg/m2 D1+Cisplatin 80mg/m2 D1(or D1-3), 3-week chemotherapy for 3 cycles. After radiation, patients receive adjuvant chemotherapy Paclitaxel 135mg/m2 D1+Cisplatin 80mg/m2 D1(or D1-3), 3-week chemotherapy for 3 cycles.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Standard dose IMRT
Description: Standard dose IMRT: GTVnx 69.69Gy, GTVnd 60-68Gy, PTV1 54.9Gy and PTV2 54Gy in 33 fractions, 5 days/week.~Induced chemotherapy: Paclitaxel 135mg/m2 D1+Cisplatin 80mg/m2 D1(or D1-3), 3-week chemotherapy for 3 cycles. After radiation, patients receive adjuvant chemotherapy Paclitaxel 135mg/m2 D1+Cisplatin 80mg/m2 D1(or D1-3), 3-week chemotherapy for 3 cycles.
Study: NCT02096133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Vitamin D3 solution
Study: NCT04387474

Intervention type: OTHER
Group type: OTHER
Intervention: Traditional rehabilitation
Description: traditional rehabilitation training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional rehabilitation
Description: traditional rehabilitation training.
Study: NCT02096133

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Placebo comparator
Study: NCT00524303

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: 4mg/kg IV loading dose followed by 2mg/kg IV weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 4mg/kg IV loading dose followed by 2mg/kg IV weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 80mg/m2 IV weekly for 4 (21 day) cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80mg/m2 IV weekly for 4 (21 day) cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80mg/m2 IV weekly for 4 (21 day) cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FEC75
Description: 5FU 500mg/m2 + Epirubicin 75 mg/m2 + cyclophosphamide 500 mg/m2 IV on day 1 of 4 (21 day) cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FEC75
Description: 5FU 500mg/m2 + Epirubicin 75 mg/m2 + cyclophosphamide 500 mg/m2 IV on day 1 of 4 (21 day) cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FEC75
Description: 5FU 500mg/m2 + Epirubicin 75 mg/m2 + cyclophosphamide 500 mg/m2 IV on day 1 of 4 (21 day) cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: 1250 mg oral daily dose in arm 2, 750 mg oral daily dose for FEC cycles and then 1000 mg oral daily dose during the Paclitaxel cycles in arm 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: 1250 mg oral daily dose in arm 2, 750 mg oral daily dose for FEC cycles and then 1000 mg oral daily dose during the Paclitaxel cycles in arm 3
Study: NCT00991900

Intervention type: DEVICE
Intervention: Measurement of oxygen saturation of retinal vessels with optical reflectometer
Description: 5 repeated measurements on both study days
Study: NCT00833859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTX (gemcitabine, docetaxel and capecitabine)
Description: GTX: 21 day cycle x 2 Gemcitabine 750mg/m2 on days 4 and 11 Taxotere® (docetaxel) 30 mg/m2 on days 4 and 11 Xeloda® (capecitabine) 750 mg/m2 on days 1-14

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiation therapy
Description: stereotactic body radiation therapy (SBRT) 25
Study: NCT00499915

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Secondhand Smoke Reduction and Smoking Cessation Counseling
Description: A secondhand smoke reduction program, including smoking cessation counseling (if appropriate), and feedback about the children's cotinine levels will be implemented using principles of Motivational Interviewing.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Asthma Education
Description: Asthma education will be provided at NICU discharge.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asthma Education
Description: Asthma education will be provided at NICU discharge.
Study: NCT06656455

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane via LMA
Description: In Group S, co-induction is used whereby the patient continues to receive 8% sevoflurane through the facemask followed after IV insertion by propofol 2mg/kg and fentanyl 1mic/kg administration. Thirty seconds afterwards, an age-appropriate LMA will be inserted. Sevoflurane is maintained initially at a concentration of 2%. The ventilation at first is assisted manually until the child starts breathing. If movement requires interruption of the exam, a bolus of propofol 1mg/kg is given and sevoflurane is increased by 1% until a maximal sevoflurane concentration of 4%. If apnea related to the depth of anesthesia occurs more than 10 sec or the saturation drops below 94%, sevoflurane will be turned off until the proper airway intervention is taken to achieve saturation above 95% and sevoflurane will be resumed at a concentration decreased by 1%.
Study: NCT03667729

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: progressive muscle relaxation
Description: intervention group: The experimental group received muscle relaxation training once a week for 3 consecutive months. The results were measured and followed up after 3 months.
Study: NCT03972683

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Handgrip Exercise Training
Description: Signaling mechanisms that regulate blood flow will be studied before and after 7 weeks of handgrip exercise training with the non-dominant forearm. Training sessions will consist of 30 min of rhythmic contractions using a handgrip exercise device, and participants will complete four training sessions per week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcholine
Description: Vasodilatory sensitivity to acetylcholine will be assessed in dose-response fashion as a standard test of vascular function. Doses of 0.5, 1.5, and 15 μg/dl forearm volume/min will be infused via a brachial artery catheter for 4 min per dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosine Triphosphate
Description: Vasodilatory sensitivity to adenosine triphosphate will be assessed during infusion of a dose of 10 μg/dl forearm volume/min administered via a brachial artery catheter over a total of 4 min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine
Description: Atropine will be used to inhibit muscarinic acetylcholine receptors in order to determine the contribution of acetylcholine to vasodilation during exercise. An initial dose of 0.2 mg will be infused via a brachial artery catheter over 3 min, then a maintenance dose of 0.067 mg will be infused over 1 min prior to each of 5 subsequent experimental trials.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Vasoconstriction to phenylephrine will be used to assess sensitivity to alpha 1 adrenergic stimulation. Phenylephrine will be infused via a brachial artery catheter at 0.125 or 0.25 μg/dl forearm volume/min (18-35 and 60-85 age groups, respectively), adjusted according to forearm blood flow, for a total of 16 min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Nitroprusside
Description: Sodium nitroprusside will be infused via a brachial artery catheter as a control vasodilator to elevate resting forearm blood flow to a level similar to that during exercise. The dose will be adjusted to match forearm blood flow to a similar level as during handgrip exercise, with an anticipated average dose of 1 μg/dl forearm volume/min. The dose will be infused for a total of 14 min.
Study: NCT02281994

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed Electromagnetic Feld (PEMF) Orthofix Cervical-Stim Model 2205OD
Description: Active devices emit PEMF signal; control devices do not emit PEMF signal.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Pulsed Electromagnetic Feld (PEMF) Orthofix Cervical-Stim Model 2205OD
Description: Active devices emit PEMF signal; control devices do not emit PEMF signal.
Study: NCT02532244

Intervention type: OTHER
Intervention: sample collection
Description: collection of blood
Study: NCT03490864

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin 1 mg
Description: Melatonin (1mg) or placebo will be administered daily during the intervention. Melatonin capsules will be obtained from Life Extension (Ft. Lauderdale, FL). The investigational drug pharmacy (IDP) at Northwestern Memorial Hospital will encapsulate the melatonin pills so the placebo (lactose) and melatonin pills appear identical. We have worked with this IDP on other projects. The investigators on this study have experience in administering melatonin for investigational and clinical purposes.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin 1 mg
Description: Melatonin (1mg) or placebo will be administered daily during the intervention. Melatonin capsules will be obtained from Life Extension (Ft. Lauderdale, FL). The investigational drug pharmacy (IDP) at Northwestern Memorial Hospital will encapsulate the melatonin pills so the placebo (lactose) and melatonin pills appear identical. We have worked with this IDP on other projects. The investigators on this study have experience in administering melatonin for investigational and clinical purposes.